Drugs / Arginine Butyrate

Trials 5 · a red edge is where a trial was stopped

199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00006340 Dec 1994 → Jul 2000 leukemia, lymphoma, precancerous condition, small intestine cancer Boston Medical Center Completed No outcome recorded
Phase 24 trials
Phase 2 NCT00992732 May → Nov 2010 lymphoid neoplasm, lymphoproliferative syndrome HemaQuest Pharmaceuticals Inc. Terminated No outcome recorded
Phase 2 NCT00917826 Sep 2008 → Sep 2009 lymphoma, lymphoproliferative syndrome HemaQuest Pharmaceuticals Inc. Terminated No outcome recorded
Phase 2 NCT00006136 Mar 1999 → ? beta-thalassemia intermedia Boston University Completed No outcome recorded
Phase 2 NCT00004412 Sep 1997 → Dec 2002 sickle cell disease, ulcer of lower limbs Susan P. Perrine Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as arginine butyrate ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006340
3

NCT00917826

NCT00004412

NCT00006136

Known as Arginine butanoate ChEMBL registry synonym — accepted as the source's own label CHEMBL6067996
Known as HQK-1004 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00992732
Known as L-arginine, butanoate (3:4) ChEMBL registry synonym — accepted as the source's own label CHEMBL6067996
Known as Vx 105 ChEMBL registry synonym — accepted as the source's own label CHEMBL6067996
Action Activate “arginine butyrate was not only effective in inducing EBV thymidine kinase transcription” PMID 9628848 Jun 1998
Modality Small molecule CHEMBL6067996
Route Intravenous “Arginine butyrate IV over 6-9 hours at night 5 days a week for 12 weeks” NCT00004412